Temozolomide Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0037 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/02/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
N/0036 
Minor change in labelling or package leaflet not 
04/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/06/2020 
16/11/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0032/G 
This was an application for a group of variations. 
28/02/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0034 
B.III.2.b - Change to comply with Ph. Eur. or with a 
07/02/2020 
n/a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IAIN/0031 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/10/2019 
16/11/2020 
SmPC, 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IB/0029 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
23/05/2018 
30/07/2018 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0028 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/07/2017 
30/07/2018 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0027/G 
This was an application for a group of variations. 
12/04/2017 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IB/0026/G 
This was an application for a group of variations. 
20/07/2016 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
Page 4/12 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
Page 5/12 
 
 
 
 
 
specification parameter as a result of a safety or 
quality issue 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0025 
A.7 - Administrative change - Deletion of 
19/04/2016 
28/04/2017 
Annex II and 
manufacturing sites 
PL 
IA/0024 
B.II.b.3.a - Change in the manufacturing process of 
13/04/2016 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
T/0023 
Transfer of Marketing Authorisation 
23/07/2015 
25/08/2015 
Labelling and 
PL 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0022 
B.II.b.1.a - Replacement or addition of a 
22/07/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/06/2015 
25/08/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/10/2014 
25/08/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0019 
Renewal of the marketing authorisation. 
26/06/2014 
26/08/2014 
SmPC, Annex 
Based on the review of the available information, the CHMP 
II and PL 
is of the opinion that the quality, the safety and the efficacy 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considers the 
benefit/risk profile of Temozolomide Teva continues to be 
favourable. 
The CHMP is also of the opinion that the renewal can be 
granted with unlimited validity. 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/01/2014 
11/02/2014 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Labelling and 
PL 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
IAIN/0017 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0016 
B.I.a.4.z - Change to in-process tests or limits 
02/05/2013 
n/a 
applied during the manufacture of the AS - Other 
variation 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/04/2013 
11/02/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0013/G 
This was an application for a group of variations. 
28/02/2013 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.3.z - Change in batch size (including batch size 
ranges) of AS or intermediate - Other variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0014 
B.II.a.1.a - Change or addition of imprints, bossing 
07/02/2013 
11/02/2014 
SmPC and PL 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
IA/0012/G 
This was an application for a group of variations. 
21/11/2012 
n/a 
B.III.1.b.2 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - New certificate for a 
starting material/reagent/intermediate/or excipient 
from a new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - Updated certificate 
from an already approved manufacturer 
B.III.1.b.3 - Submission of a new or updated Ph. Eur. 
TSE Certificate of suitability - Updated certificate 
from an already approved manufacturer 
IB/0011 
In line with the CHMP adoption of variations to the 
09/10/2012 
25/10/2012 
SmPC, Annex 
Marketing Authorisation of the Originator Product 
Temodal (EMEA/H/C222/II/59) on 24.05.2012 the 
Product Information (PI) for Temozolomide Teva was 
updated with changes to the SmPC in order to add a 
II, Labelling 
and PL 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
warning regarding the risk of myelosuppression 
including prolonged pancytopenia following the 
assessment of PSUR. The package leaflet was 
improved and brought in line accordingly. 
Furthermore, the PI is brought in line with the latest 
QRD template, version 8. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0010 
B.II.b.2.b.1 - Change to batch release arrangements 
13/06/2012 
25/10/2012 
Annex II and 
and quality control testing of the FP - Not including 
PL 
batch control/testing 
IA/0009/G 
This was an application for a group of variations. 
21/02/2012 
n/a 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0008/G 
This was an application for a group of variations. 
26/01/2012 
31/05/2012 
SmPC, 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
Labelling and 
PL 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0007 
B.II.d.2.a - Change in test procedure for the finished 
21/12/2011 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/11/2011 
31/05/2012 
SmPC, Annex 
To update section 4.8 of the SMPC to include information 
generic/hybrid/biosimilar products following 
II, Labelling 
on possible risk of hepatotoxicity associated with 
assessment of the same change for the reference 
and PL 
Temozolomid identified following a cumulative review. The 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
PL is updated accordingly.  Additionally, formal, linguistic 
and formatting changes were introduced to align with the 
reference product information.  Furthermore, contact 
details of a manufacturer and local representatives were 
amended. 
N/0005 
Minor change in labelling or package leaflet not 
31/05/2011 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0004 
A.5.a - Administrative change - Change in the name 
19/01/2011 
n/a 
Annex II and 
and/or address of a manufacturer responsible for 
PL 
batch release 
IB/0003 
B.II.b.3.z - Change in the manufacturing process of 
26/11/2010 
n/a 
the finished product - Other variation 
IB/0002/G 
This was an application for a group of variations. 
12/07/2010 
n/a 
B.II.b.1.e - Replacement or addition of a 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
IA/0001/G 
This was an application for a group of variations. 
23/04/2010 
n/a 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.b.2 - Change to batch release arrangements 
and quality control testing of the FP - Including batch 
control/testing 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
